Features Pricing Learn Reverse Splits Tracker Shelf & ATM Tracker Warrant Tracker PIPE Deal Tracker Weekly Report FAQ API Sign In →
52 /100
HIGH RISK
Score updated Aug 28, 2026

LSTA — Lisata Therapeutics, Inc. Dilution Risk Tracker

Track LSTA dilution risk with DilutionWatch's stock tracker. DilutionScore™ measures dilution risk across 5 factors — lower scores indicate higher risk of share dilution.

⚠️ Not financial advice. Do your own research before making any investment decisions.

🔔 Track LSTA — Get alerts when the score changes →

As of August 28, 2026, Lisata Therapeutics, Inc. (LSTA) has a DilutionWatch DilutionScore of 52/100, rated HIGH dilution risk. Lisata Therapeutics, Inc. has a market capitalization of $29.60M, 9.01M shares outstanding.

This page includes automatically generated factual summaries from DilutionWatch data. It is not financial advice, not investment research, and not a recommendation. Do your own research. Read the full disclaimer and terms of service.

Score Breakdown

📋 Offering Ability
40
💰 Cash Runway
85
📊 Float Risk
27
⚠️ Warrant Exposure
40
🔄 Convertible Debt
40

Dilution Forecast

Watch
Minor dilution signals detected
model est. 22%
💰 Capital Raise model 35%
• Low cash runway: 5 months remaining
🔄 Reverse Split model est. 15%
• Only 5 months cash — financial pressure
🔔 Track LSTA — Get forecast alerts →

Market Data

Market Cap$29.60M
Shares Outstanding9.01M
Float7.19M
Cash$10.44M
DebtN/A
Short InterestN/A

Institutional Holdings

11.3% institutional ownership
Source: Yahoo Finance · Detailed 13F holder data available for tracked tickers
🔔 Track LSTA for full holder detail →

Short Interest

Short Interest56.3K
Days to Cover1.0
% of Float0.8%
FINRA data as of Jul 31, 2026

Recent SEC Activity

xbrl XBRL CONVERTIBLE 2010-12-31
4 INSIDER TRANSACTION 2026-01-13
4 INSIDER TRANSACTION 2026-01-13
4 INSIDER TRANSACTION 2026-01-13
4 INSIDER TRANSACTION 2026-01-13
Full SEC filing analysis available with free account

Recent News

No recent news

Factual LSTA Dilution Snapshot

Lisata Therapeutics, Inc. (LSTA) has a DilutionScore of 52/100, rated High dilution risk. Score date: August 28, 2026.

This automatically generated snapshot is assembled from stored DilutionWatch data fields and may contain data-source errors or omissions. It is not financial advice, not investment research, and not a recommendation. Do your own research and review the full disclaimer and terms of service.

Track LSTA Dilution Risk in Real-Time
Get instant alerts when SEC filings impact dilution risk. Free tier available.
Start Tracking LSTA — Free
Real-time SEC alerts DilutionScore™ tracking No credit card required

Related Stocks — HIGH Risk

Other HIGH dilution risk stocks tracked by DilutionWatch with similar profiles:

→ Biotech / Pharma sector dilution risk overview

Browse all 8,024+ tracked stocks →

📖 Dilution Education
→ Complete Dilution Guide for Retail Investors → Anti-Dilution Provisions Explained → Stock Dilution Red Flags to Watch → Understanding Shelf Registrations
More Research for LSTA
LSTA FDA Catalyst Timeline & Biotech Grade — BiotechSigns

Part of the Guerilla Finance research network. Cross-reference multiple data sources for better due diligence.